XIENCE 28 Global Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 963 participants.

Also called NCT03355742

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 963 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03355742
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Austria, Belgium, China, Germany, Hong Kong SAR China, Italy, Netherlands, Portugal, Singapore, Spain, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03355742. Allocation not applicable; no masking; primary purpose treatment. Start 2018-02-09 (actual); primary completion 2019-10-24 (actual). Results posted on 2021-02-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
XIENCE 28 Global Study
Condition
Bleeding Disorder
Condition
Stroke, Ischemic
Condition
Stroke Hemorrhagic
Condition
Hematological Disease
Condition
Thrombocytopenia
Condition
Coagulation Disorder
Condition
Anemia
Condition
Renal Insufficiency
Intervention (Device)
XIENCE
Intervention (Drug)
DAPT
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct03355742
Content hash
04b348304a4978b9707f92da7ded3f45a0b327df4ab40e4773cb73e0d58fafda